Infographic | April 16, 2021

Covid's Impact on Outsourced Small Molecule Manufacturing

Source: ISR Reports

In Q42020, ISR surveyed 249 sponsors who outsource small molecule manufacturing to learn if their company experienced outsourced manufacturing complications as a result of the Covid-19 pandemic. Small molecule drug substance outsourcers were slightly more likely to report complications than small molecule drug substance outsourcers, 45% vs 40%.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online